9R5 Stock Overview
Spermosens AB engages in the research, development, and commercialization of diagnostic technology in health and medical care in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Spermosens AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.012 |
| 52 Week High | kr0.08 |
| 52 Week Low | kr0.0078 |
| Beta | 0.30 |
| 1 Month Change | -1.69% |
| 3 Month Change | -63.86% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -82.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9R5 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 16.0% | -2.2% | 2.5% |
| 1Y | n/a | -25.2% | 6.0% |
Return vs Industry: Insufficient data to determine how 9R5 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 9R5 performed against the German Market.
Price Volatility
| 9R5 volatility | |
|---|---|
| 9R5 Average Weekly Movement | 55.9% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9R5's share price has been volatile over the past 3 months.
Volatility Over Time: 9R5's weekly volatility has increased from 35% to 56% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 7 | Tore Duvold | www.spermosens.com |
Spermosens AB engages in the research, development, and commercialization of diagnostic technology in health and medical care in Sweden. The company provides male infertility fertility diagnostics and fertility treatments for the IVF market. It develops JUNO-Checked, a device that measures the binding between sperm and egg cell to enable individualized choice of fertility treatment based on measured binding.
Spermosens AB Fundamentals Summary
| 9R5 fundamental statistics | |
|---|---|
| Market cap | €598.02k |
| Earnings (TTM) | -€1.05m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs 9R5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9R5 income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr12.20m |
| Earnings | -kr12.20m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 30, 2024
| Earnings per share (EPS) | -0.30 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 75.0% |
How did 9R5 perform over the long term?
See historical performance and comparison